Moolec Science (NASDAQ:MLEC – Get Free Report) is one of 495 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Moolec Science to similar companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Insider and Institutional Ownership
0.1% of Moolec Science shares are held by institutional investors. Comparatively, 33.5% of shares of all “Biotechnology” companies are held by institutional investors. 19.9% of Moolec Science shares are held by company insiders. Comparatively, 19.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Moolec Science and its peers top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Moolec Science | $5.63 million | -$7.31 million | -4.35 |
Moolec Science Competitors | $211.82 million | -$15.63 million | 125.19 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Moolec Science and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Moolec Science | 0 | 0 | 1 | 0 | 3.00 |
Moolec Science Competitors | 963 | 2820 | 7059 | 106 | 2.58 |
Moolec Science presently has a consensus target price of $6.00, suggesting a potential upside of 589.73%. As a group, “Biotechnology” companies have a potential upside of 28.90%. Given Moolec Science’s stronger consensus rating and higher possible upside, analysts plainly believe Moolec Science is more favorable than its peers.
Profitability
This table compares Moolec Science and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Moolec Science | -129.97% | -93.88% | -33.37% |
Moolec Science Competitors | -7,267.69% | -105.83% | -28.54% |
Risk & Volatility
Moolec Science has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s peers have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.
Summary
Moolec Science beats its peers on 7 of the 13 factors compared.
Moolec Science Company Profile
Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.
Receive News & Ratings for Moolec Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moolec Science and related companies with MarketBeat.com's FREE daily email newsletter.